Scholar Rock (NASDAQ:SRRK) Given "Outperform" Rating at Wedbush

Scholar Rock (NASDAQ:SRRK - Get Free Report)'s stock had its "outperform" rating reiterated by research analysts at Wedbush in a note issued to investors on Monday,RTT News reports. They currently have a $50.00 price target on the stock. Wedbush's price target would suggest a potential upside of 50.11% from the stock's current price.

SRRK has been the subject of several other reports. Truist Financial lifted their price target on shares of Scholar Rock from $36.00 to $45.00 and gave the company a "buy" rating in a report on Monday, November 25th. HC Wainwright upped their target price on shares of Scholar Rock from $40.00 to $50.00 and gave the company a "buy" rating in a research report on Tuesday, November 26th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $40.86.

Scholar Rock Price Performance

Shares of SRRK stock traded down $0.33 on Monday, hitting $33.31. 277,749 shares of the stock traded hands, compared to its average volume of 1,142,628. The firm has a market cap of $3.15 billion, a price-to-earnings ratio of -14.17 and a beta of 0.59. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88. The firm has a 50 day simple moving average of $38.89 and a two-hundred day simple moving average of $31.88. Scholar Rock has a 52 week low of $6.76 and a 52 week high of $46.98.

Remove Ads

Insider Buying and Selling

In other Scholar Rock news, Director Katie Peng sold 1,006 shares of Scholar Rock stock in a transaction on Monday, March 17th. The stock was sold at an average price of $34.42, for a total transaction of $34,626.52. Following the completion of the sale, the director now directly owns 30,319 shares of the company's stock, valued at $1,043,579.98. The trade was a 3.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Edward H. Myles sold 142,292 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $35.62, for a total value of $5,068,441.04. Following the transaction, the chief financial officer now directly owns 111,345 shares in the company, valued at $3,966,108.90. The trade was a 56.10 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 293,272 shares of company stock valued at $11,030,778 in the last 90 days. Company insiders own 19.20% of the company's stock.

Hedge Funds Weigh In On Scholar Rock

Hedge funds and other institutional investors have recently modified their holdings of the business. GAMMA Investing LLC lifted its stake in shares of Scholar Rock by 51.8% during the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company's stock worth $34,000 after purchasing an additional 269 shares during the last quarter. Quarry LP raised its holdings in Scholar Rock by 3,443.3% in the third quarter. Quarry LP now owns 4,500 shares of the company's stock worth $36,000 after purchasing an additional 4,373 shares in the last quarter. Global Retirement Partners LLC lifted its position in shares of Scholar Rock by 584.7% during the fourth quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock valued at $39,000 after buying an additional 766 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of Scholar Rock by 1,321.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company's stock valued at $48,000 after buying an additional 1,031 shares in the last quarter. Finally, GF Fund Management CO. LTD. purchased a new position in shares of Scholar Rock in the 4th quarter worth approximately $85,000. 91.08% of the stock is currently owned by institutional investors.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.